“We’re advancing REC-3565, a potential best-in-class MALT1 inhibitor, to improve outcomes for patients with B-cell malignancies with limited treatment options,” said David Mauro, Chief Medical Officer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback